# Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

> **NCT01562561** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 213 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide
- **DRUG:** insulin NPH

## Key facts

- **NCT ID:** NCT01562561
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06-01
- **Primary completion:** 2002-12-20
- **Final completion:** 2002-12-20
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562561, "Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01562561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*